Veracyte: Accelerating Growth, Expanding Margins, and Pipeline-Driven Upside Support a Raised $48 Price Target

Analyst Michael Matson from Needham maintained a Buy rating on Veracyte and increased the price target to $48.00 from $44.00.

Michael Matson has given his Buy rating due to a combination of factors, most notably Veracyte’s accelerating top-line growth and improving profitability metrics. The company’s fourth-quarter 2025 revenue modestly exceeded its earlier indication, and margins expanded meaningfully year over year, supported by strong testing volumes in key franchises such as Decipher and Afirma.

Management’s confidence in sustaining double-digit growth over the next several years is underpinned by a robust pipeline that includes MRD tests, expanded kitted offerings in Europe, and the Percepta nasal swab test, all of which should add incremental revenue streams. In addition, Veracyte’s debt-free balance sheet, sizable cash position, and positive earnings and cash flow provide financial flexibility, leading Matson to lift his price target to $48 based on projected 2027 revenue.